Diagnostic value of quantification of circulating free DNA for gall bladder cancer using a chemiluminescence DNA biosensor system based on DNA G-quadruplex/ hemin enzyme

Hua, Ying; Fengying, Sun; Hu, Feng; Wu, Yanhong; Xia, Xianru; Xiaolei, Tang

doi:10.1016/j.tranon.2020.100928

Cited by 9 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the discrimination of LN involvement, the sensitivity, specificity, and diagnostic accuracy reached up to 83.87%, 55.0%, and 72.5%, respectively, using a cut-off value of >0.4049 [ 88 ]. Thus, it seems that this method provides good sensitivity, specificity, and diagnostic accuracy for differentiating GBC from other diseases, in particular when using a chemiluminescence DNA biosensor method, possibly leading to the use of this approach in the coming years to obtain an early diagnosis [ 89 ].…”

Section: Novel Approaches For Gbc Staging and Managementmentioning

confidence: 99%

Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives

et al. 2022

View full text Add to dashboard Cite

Gallbladder carcinoma (GBC) is a rare malignancy, with an estimated 5-year survival rate of less than 5% in the case of advanced disease. Surgery is the only radical treatment for early stages, but its application and effectiveness depend on the depth of tumoral invasion. The extent of resection is usually determined according to the T-stage. Therefore, an early and correct preoperative assessment is important for the prognosis, as well as for the selection of the most appropriate surgical procedure, to avoid unnecessary morbid surgeries and to reach the best outcomes. Several modalities can be used to investigate the depth of invasion, from ultrasounds to CT scans and MRI, but an ideal method still does not exist. Thus, different protocols are proposed according to different recommendations and institutions. In this scenario, the indications for laparoscopic and robotic surgery are still debated, as well as the role of new technologies such as next-generation sequencing and liquid biopsies. The aim of this article is to summarize the state of the art current modalities and future perspectives for assessing the depth of invasion in GBC and to clarify their role in perioperative management accordingly.

show abstract

Section: Novel Approaches For Gbc Staging and Managementmentioning

confidence: 99%

Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Due to the challenge of early diagnosis and the high malignant degree of late diagnosis, there is no specific and effective treatment for GBC. Similar to the vast majority of malignant tumors, surgical resection is still the only available curative strategy for GBC ( Ying et al., 2021 ), but only 10 percent of patients are currently in a stage suitable for surgical resection ( Goel et al., 2021 ). Incidental GBC cases are often found by pathological examination after cholecystectomy, requiring secondary surgery ( Ethun et al., 2017 ), while symptomatic patients are usually at an advanced stage who are not suitable for surgery or have poor surgical outcomes ( Liu et al., 2022b ).…”

Section: Introductionmentioning

confidence: 99%

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

Liu,

Li,

Chen

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary system with the worst prognosis. Even after radical surgery, the majority of patients with GBC have difficulty achieving a clinical cure. The risk of tumor recurrence remains more than 65%, and the overall 5-year survival rate is less than 5%. The gut microbiota refers to a variety of microorganisms living in the human intestine, including bacteria, viruses and fungi, which profoundly affect the host state of general health, disease and even cancer. Over the past few decades, substantial evidence has supported that gut microbiota plays a critical role in promoting the progression of GBC. In this review, we summarize the functions, molecular mechanisms and recent advances of the intestinal microbiota in GBC. We focus on the driving role of bacteria in pivotal pathways, such as virulence factors, metabolites derived from intestinal bacteria, chronic inflammatory responses and ecological niche remodeling. Additionally, we emphasize the high level of correlation between viruses and fungi, especially EBV and Candida spp., with GBC. In general, this review not only provides a solid theoretical basis for the close relationship between gut microbiota and GBC but also highlights more potential research directions for further research in the future.

show abstract

“…10 Many gene sequences such as the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, ß-globin-gene, human telomerase reverse transcriptase (hTERT), LINE1 (long interspersed nucleotide elements) were studied as biomarkers in breast cancer. 17 The Arthrobacter luteus (ALU) sequences were chosen because they are the most common and active repeated elements in the human genome. They typically have a length of 300 nucleotides and make up more than 10% of the genome.…”

Section: Introductionmentioning

confidence: 99%

The role of circulating cell-free DNA and its integrity as a biomarker for diagnosis of breast cancer using ALU (247/115) bP sequences

Hafeez

Rahman

Kamel

et al. 2023

EJI

View full text Add to dashboard Cite

of breast cancer by using sensitive and specific biomarkers is necessary. Cell– free DNA (cf-DNA) is a candidate biomarker in various cancers. Contrasting, shorted uniformed DNA released from apoptotic non-diseased cells, DNA released from malignant cells varies in size. DNA integrity is a ratio between 247 and 115 bp. This study aimed to evaluate the diagnostic values of cf-DNA using ALU -247 and ALU- 115 and DNA integrity in peripheral blood of breast cancer patients as a noninvasive marker. Also, to determine correlations between ALU-247 and ALU-115, DNA integrity, cancer antigen (CA )15-3 and carcinoembryonic antigen (CEA) with each other in breast cancer patients and in different stages of breast cancer. This study included 100 females, divided into 3 groups. The first group consisted of 20 apparently healthy females as the control group. The second group included 20 patients with benign breast lesions. The third group included 60 patients with breast cancer. Serum levels of both ALU-247 and ALU-115 as well as cf-DNA integrity were statistically significant higher in breast cancer patients as compared to the control group (p=0.018, p<0.001 and p=0.009 respectively). Compared to the control group, ALU-247 had the best diagnostic sensitivity for diagnosis of breast cancer (86.78%) with 75% specificity with area under the curve of 0.848. We concluded that measuring ALU-247, ALU-115 and DNA integrity in peripheral blood would be a promising novel approach for diagnosis and early detection of breast cancer.

show abstract

Diagnostic value of quantification of circulating free DNA for gall bladder cancer using a chemiluminescence DNA biosensor system based on DNA G-quadruplex/ hemin enzyme

Cited by 9 publications

References 36 publications

Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives

Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

The role of circulating cell-free DNA and its integrity as a biomarker for diagnosis of breast cancer using ALU (247/115) bP sequences

Contact Info

Product

Resources

About